Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 12,623 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period A Clear all
Recruiting No phase listed Observational

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

NCT05224778
View directory record Official record
Conditions
Congenital Myotonic Dystrophy, CDM
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 59 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

NCT07149415
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone, Omeprazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Caring Connections: A Program to Alleviate Social Isolation and Loneliness in Individuals Living With Spinal Cord Injury

NCT05295108
View directory record Official record
Conditions
Spinal Cord Injuries and Disorders (SCI/D)
Interventions
Caring Connections, Attention control
Other
Lead sponsor
Chicago Association for Research and Education in Science
Other
Eligibility
18 Years to 90 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans

NCT06627569
View directory record Official record
Conditions
Overweight/Obesity, Stress
Interventions
Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

NCT01940341
View directory record Official record
Conditions
HBeAg-negative Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

NCT02112994
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
8 Months and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

NCT01999322
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522
View directory record Official record
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
San Diego, California • Springfield, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

NCT01454622
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Feasibility Trial of an Online Course (eMB) to Reduce Anxiety and Depression for Pregnant Women and Their Partners

NCT05867680
View directory record Official record
Conditions
Anxiety Disorders Generalized, Depression
Interventions
Online Mothers and Babies Course (eMB)
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Phase 2 Interventional

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

NCT07392580
View directory record Official record
Conditions
Laryngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Epinephrine injection, Laryngeal Biopsy, Endoscopic Surgery
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

NCT06462404
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
E2086, E2086 Placebo, Active Comparator, Active Comparator Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Santa Ana, California • Miami, Florida • Macon, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

NCT04690855
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Talazoparib, Atezolizumab, Radiation
Drug · Radiation
Lead sponsor
Mylin A. Torres, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Centralized Screening Unit (CSU) at Montefiore-Einstein

NCT06284408
View directory record Official record
Conditions
Lung Cancer
Interventions
Centralized Screening Unit Implementation
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years to 77 Years
Enrollment
9,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

DOMPE -MT Neurotrophic Keratitis

NCT06947850
View directory record Official record
Conditions
Dry Eye, Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

NCT03390491
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
OnTrack>TheGame (OTG), Recovery Videos (RV)
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
16 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short Term Ketone Supplementation and Cardiometabolic Health

NCT04236388
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Ketone drink, Placebo drink
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
50 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families

NCT05875142
View directory record Official record
Conditions
Community Reinforcement And Family Training, Family Health, Substance-Related Disorders
Interventions
Behavioral: Digital Tutorial Overview, Behavioral: Training Materials, Behavioral: Feedback and Coaching
Behavioral
Lead sponsor
We The Village, Inc.
Other
Eligibility
19 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

NCT00602342
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Creating Live Interactions to Mitigate Barriers

NCT03317769
View directory record Official record
Conditions
Schizophrenia
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

NCT03706469
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 T2, TAK-831 T3
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FITT Exercise Counseling With Interactive Accelerometry and Physical Activity in Adolescents at Increased Risk of Early Cardiovascular Disease: A Pilot Study

NCT01394705
View directory record Official record
Conditions
Coronary Artery Disease Risk High
Interventions
BodyMedia
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 21 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

NCT01475253
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Lidocaine Releasing Intravesical System - LiRIS®, LiRIS Placebo, Sham Cystoscopy Procedure
Drug · Other · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Glendale, Arizona • Glendora, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 29, 2026, 2:34 AM EDT